HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.
Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.
An all-oral regimen of daclatasvir plus simeprevir, without interferon or ribavirin, led to sustained response in 85% to 95% of patients with hepatitis C genotype 1b, but this combination did not work well against genotype 1a, researchers reported last week at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston.
A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1 hepatitis C infection, Rajendar Reddy of the University of Pennsylvania Hospital told the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston on Tuesday. This is expected to be the first approved interferon- and ribavirin-free combination for genotype 1b, available by the end of 2014.
The next-generation non-nucleoside reverse transcriptase inhibitor doravirine (formerly MK-1439) showed potent antiretroviral activity and good tolerability in combination with tenofovir/emtricitabine (the drugs in Truvada) in a dose-finding study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) last week in Boston.